Perrigo Company plc (PRGO)
Pre-market:
| Previous close | 32.90 |
| Open | 33.11 |
| Bid | 0.00 x 1000 |
| Ask | 35.00 x 3200 |
| Day's range | 32.76 - 33.35 |
| 52-week range | 25.77 - 40.28 |
| Volume | |
| Avg. volume | 1,952,359 |
| Market cap | 4.48B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.03 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | 1.10 (3.34%) |
| Ex-dividend date | 31 May 2024 |
| 1y target est | 40.50 |
PR NewswirePerrigo Announces Quarterly Dividend
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024.
ZacksPerrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
- PR Newswire
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
